I have to agree. I took a position under the impression that things were on track with initial trial info, unfortunately, that unforeseen 30 day delay has made it tough to stay positive. Perhaps this biotech is better than my last, but lack of info MF stated would have been out by now, 210 enrollment not results, is challenging. Science seems sound for sure, imo. I'm in, and understand it's not MF job to appease shareholders, but a touch of something is too much to ask at the moment, so we wait.
Market Data 
Markets 
AI
